NCT00196755已完成3 期
An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride (Renagel®) Compared With Calcium Acetate in Peritoneal Dialysis Patients
Genzyme, a Sanofi Company17 个研究点 分布在 7 个国家目标入组 138 人开始时间: 2004年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 138
- 试验地点
- 17
- 主要终点
- Compare the effects of sevelamer dosed three times per day (TID) and calcium acetate dosed TID on serum phosphorus.
研究概览
简要总结
The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to sign an informed consent form.
- •Men or women aged 18 years of age or older.
- •A diagnosis of Chronic Kidney Disease (CKD) and receiving peritoneal dialysis (Continuous cyclical peritoneal dialysis (CAPD), Automated peritoneal dialysis (APD) or Continuous cyclical peritoneal dialysis (CCPD) for 8 weeks or longer.
- •In the opinion of the investigator, expected to receive peritoneal dialysis for the duration of the study.
- •Will have a serum phosphorus level >1.76 mmol/L(5.50 mg/dL) after 2 weeks washout from their usual phosphate binder.
- •Will have serum calcium measurement adjusted for albumin within the range (2.10-2.60 mmol/L (8.40-10.40 mg/dL) following 2 weeks washout from their usual phosphate binder.
- •Willing to maintain the prescribed sevelamer or calcium acetate for the duration of the study.
- •Considered compliant with phosphate binders and dialysis.
- •On a stable doses of medication to treat hyperparathyroidism (Vitamin D or its analogues or calcimimetic agents) for the month prior to screening.
- •Willing to discontinue use of antacids containing calcium, aluminium or magnesium at screening visit for the duration of the study (unless taken as an evening calcium supplement as prescribed by the investigator per protocol).
- •Willing to avoid intentional changes in diet such as fasting or dieting.
- •If female and of childbearing potential (pre-menopausal and not surgically sterile), willing to use an effective contraceptive method throughout study, which includes barrier methods, hormones, or Intrauterine devices (IUDs).
- •Have a level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel.
排除标准
- •Patients with a history of peritonitis in the last 30 days or > 2 episodes in the last 12 months
- •Patient with active dysphagia, swallowing disorder, bowel obstruction, or severe gastrointestinal motility disorder.
- •Patients who in the opinion of the investigator have poorly controlled diabetes mellitus, poorly controlled hypertension, active vasculitis, Human Immunodeficiency Virus (HIV) infection, or any clinically significant, unstable medical condition.
- •Patients with any evidence of active malignancy except for basal cell carcinoma of the skin. A history of malignancy is not exclusion.
- •Current use of an antiarrhythmic medication such as quinidine, procainamide, tocainide, or amiodarone for the control of arrhythmias.
- •Current use of a seizure medication such as phenytoin, phenobarbital, valproate, or carbamazepine for the control of a seizure disorder.
- •Active ethanol or drug abuse, excluding tobacco use.
- •If female, are pregnant, planning on becoming pregnant in the next 6 months or breast-feeding.
- •Patients with a known hypersensitivity to sevelamer or any constituents of either study drug.
- •Patients who have participated in a study of an investigational drug/device during the 30 days preceding the start of the screening period.
- •Patients who have any other condition, which in the opinion of the investigator will prohibit the patient's participation in the study.
- •Patient is unable to comply with the requirements of the protocol.
研究组 & 干预措施
Sevelamer Hydrochloride (Renagel®)
Experimental
干预措施: Sevelamer Hydrochloride (Renagel®) (Drug)
Calcium acetate (PhosLo® )
Active Comparator
干预措施: Calcium acetate (PhosLo® ) (Drug)
结局指标
主要结局
Compare the effects of sevelamer dosed three times per day (TID) and calcium acetate dosed TID on serum phosphorus.
时间窗: 12 weeks
次要结局
- Serum calcium- phosphorus (CaxPO4) product(12 weeks)
- Serum lipids - total and LDL cholesterol, non- HDL cholesterol, HDL, triglycerides(12 weeks)
- Plasma biomarkers: random blood glucose, glycosylated haemoglobin, bone specific alkaline phosphatase, uric acid and c-reactive protein(12 weeks)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
4 期
Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis PatientsChronic Kidney DiseaseNCT01427907Fresenius Medical Care North America38
已完成
3 期
Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis PatientsChronic Kidney DiseaseNCT00267514Genzyme, a Sanofi Company31
已完成
2 期
A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU SubjectsHypocalcemiaNCT00053378Abbott45
已完成
4 期
Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis PatientsHemodialysisCardiovascular EventsHyperphosphatemiaNCT01755078Chugai Pharma Taiwan166
终止
4 期
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. ParicalcitolKidney FailureSecondary HyperparathyroidismHypercalcemiaHyperphosphatemiaNCT01725113Winthrop University Hospital16